Unmet Need in Hemophilia B and The Value of Gene Therapy

Webinar recorded May 18, 2022
Sponsored by CSL Behring

Hemophilia B is a rare, X-linked, genetic disorder.  People with the condition are particularly vulnerable to bleeds in their muscles, internal organs, and joints, leading to pain, swelling, and joint damage.  Current treatment includes lifelong prophylactic infusions of factor IX (FIX) to temporarily replace or supplement low levels of the blood-clotting factor.  Prophylactic treatment is associated with a significant economic burden and despite treatment, clinical burdens still exist.  For people with hemophilia B, gene therapy has the potential to sustain blood-clotting ability by addressing the cause of the condition:  a faulty gene for FIX.

Speakers:

Debbie Bensen-Kennedy, MD
Vice president Medical Affairs
CSL Behring Biotherapies for Life™

Robert Rouse, MS
Head of US Market Access
CSL Behring Biotherapies for Life™

This webinar is sponsored, developed, and presented by the sponsor.  The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by: